CommercialCoverageMedium impact
06.02.27p, Assays of Genetic Expression in Tumor Tissue for Breast Cancer Prognosis (Independence Administrators)
Independence Blue Cross·Oncology, Hematology·Medical Policy
Effective date
Mar 5, 2025
We identified it
Jun 19, 2026
Summary
Independence Administrators has reissued their policy for genetic expression assays in tumor tissue for breast cancer prognosis. This is a policy reissuance with an effective date of March 5, 2025, but specific changes to coverage or billing requirements are not detailed in the summary provided.
Action Required
By March 5, 2025: Billing team should review the full policy document at the provided URL to identify any changes to coverage criteria, prior authorization requirements, or billing guidelines for genetic expression assays in breast cancer. Update billing procedures and prior authorization workflows as needed based on the detailed policy content.